<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466985</url>
  </required_header>
  <id_info>
    <org_study_id>1439-005</org_study_id>
    <secondary_id>2011-003508-19</secondary_id>
    <secondary_id>MK-1439-005</secondary_id>
    <nct_id>NCT01466985</nct_id>
  </id_info>
  <brief_title>A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-1439 in HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety, tolerability, pharmacokinetics, and antiretroviral
      activity of doravirine (MK-1439) as monotherapy in antiretroviral therapy (ART)-naïve,
      HIV-1-infected participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 21, 2011</start_date>
  <completion_date type="Actual">April 10, 2012</completion_date>
  <primary_completion_date type="Actual">April 10, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>The change from baseline to Day 7 in plasma HIV RNA viral load was determined for each arm. Results are expressed as change in HIV RNA log10 copies/mL after 7 daily doses of doravirine or placebo. It was hypothesized that at least 1 dose of doravirine would be superior to placebo as documented by the upper bound of the 90% confidence interval &lt;-1. Plasma HIV RNA levels were determined using the Abbott RealTime HIV assay which has a linear range from 40 to 10 million copies/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of Doravirine on Day 7</measure>
    <time_frame>Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7</time_frame>
    <description>The AUC0-24hr of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Doravirine on Day 7</measure>
    <time_frame>Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7</time_frame>
    <description>The Cmax of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration 24 Hours Postdose (C24hr) of Doravirine on Day 7</measure>
    <time_frame>24 hours postdose on Day 7 (Day 8)</time_frame>
    <description>The C24hr of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Doravirine on Day 7</measure>
    <time_frame>Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7</time_frame>
    <description>The Tmax of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Panel A: Doravirine 25 mg or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral doses of doravirine 25 mg or placebo once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B: Doravirine 200 mg or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel B (doravirine 200 mg or placebo once daily for 7 days) will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C: Doravirine or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine</intervention_name>
    <description>Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).</description>
    <arm_group_label>Panel A: Doravirine 25 mg or Placebo</arm_group_label>
    <arm_group_label>Panel B: Doravirine 200 mg or Placebo</arm_group_label>
    <arm_group_label>Panel C: Doravirine or Placebo</arm_group_label>
    <other_name>MK-1439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets once daily for 7 days.</description>
    <arm_group_label>Panel A: Doravirine 25 mg or Placebo</arm_group_label>
    <arm_group_label>Panel B: Doravirine 200 mg or Placebo</arm_group_label>
    <arm_group_label>Panel C: Doravirine or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of HIV-1-infection ≥3 months prior to screening

          -  Participants with female partner(s) of child-bearing potential must agree to use a
             medically acceptable method of contraception during the study and for 90 days after
             the last dose of study drug

          -  Body Mass Index (BMI) ≤35 kg/m^2

          -  Other than HIV infection, participant's baseline health is judged to be stable

          -  No clinically significant abnormality on electrocardiogram (ECG)

          -  Participant is ART-naïve (defined as having never received any antiretroviral agent or
             ≤30 consecutive days of an investigational antiretroviral agent (excluding an
             Non-Nucleoside Reverse Transcriptase Inhibitor [NNRTI]) or ≤60 consecutive days of
             combination ART not including an NNRTI)

          -  Participant is willing to receive no other ART for the duration of the treatment phase
             of this study.

        Exclusion Criteria:

          -  History of stroke, chronic seizures, or major neurological disorder

          -  History of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, hepatic, immunological (outside of HIV-1 infection), renal,
             respiratory, or genitourinary abnormalities or diseases

          -  History of clinically significant neoplastic disease

          -  Participant has used any immune therapy agents or immunosuppressive therapy within 1
             month prior to treatment in this study

          -  Participant has one or more pre-existing risk factors for Torsades de Pointes (New
             York Heart Association Functional Classification II through IV heart failure, familial
             long-QT-syndrome, uncorrected hypokalemia, QTcF &gt;470 msec)

          -  Participant requires or is anticipated to require chronic daily prescription
             medications

          -  Current (active) diagnosis of acute hepatitis due to any cause

          -  History of chronic Hepatitis C virus (HCV) unless there has been documented cure
             and/or patient with a positive serologic test for HCV has a negative HCV viral load.

          -  Positive Hepatitis B surface antigen

          -  Participant is unable to refrain from or anticipates the use of any medication,
             including prescription and non-prescription drugs or herbal remedies (such as St.
             John's Wort [Hypericum perforatum]) beginning approximately 2 weeks (or 5 half-lives)
             prior to administration of the initial dose of study drug, throughout the study, until
             the post-study visit

          -  Participant consumes excessive amounts of alcohol, defined as greater than 3 glasses
             of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10
             ounces], wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day

          -  Participant consumes excessive amounts, defined as greater than 6 servings (1 serving
             is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other
             caffeinated beverages per day

          -  Participant is an excessive smoker (i.e., more than 10 cigarettes/day) and is
             unwilling to restrict smoking to ≤10 cigarettes per day

          -  Major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks
             prior to the prestudy (screening) visit

          -  Participation in another investigational study within 4 weeks prior to the prestudy
             (screening) visit

          -  History of significant multiple and/or severe allergies (including latex allergy), or
             has had an anaphylactic reaction or significant intolerability to prescription or
             non-prescription drugs or food

          -  Current regular user (including use of any illicit drugs) or has a history of drug
             (including alcohol) abuse within approximately 1 year
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <reference>
    <citation>Schürmann D, Sobotha C, Gilmartin J, Robberechts M, De Lepeleire I, Yee KL, Guo Y, Liu R, Wagner F, Wagner JA, Butterton JR, Anderson MS. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals. AIDS. 2016 Jan 2;30(1):57-63. doi: 10.1097/QAD.0000000000000876.</citation>
    <PMID>26372481</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>November 4, 2011</study_first_submitted>
  <study_first_submitted_qc>November 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <results_first_submitted>September 24, 2018</results_first_submitted>
  <results_first_submitted_qc>September 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2019</results_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with human immunodeficiency virus type 1 (HIV-1) who were antiretroviral therapy (ART)-naïve were enrolled at a single study center in Germany.</recruitment_details>
      <pre_assignment_details>Participants were allocated into panels, then randomized to doravirine 25 mg or placebo (Panel A) or doravirine 200 mg or placebo (Panel B). The protocol planned for a possible Panel C but Panel C was not enrolled. Study results are presented according to actual treatment received.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Doravirine 25 mg</title>
          <description>Participants with HIV-1 infection received doravirine 25 mg q.d. for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Doravirine 200 mg</title>
          <description>Participants with HIV-1 infection received doravirine 200 mg q.d. for 7 days.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants with HIV-1 infection received placebo q.d. by mouth for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doravirine 25 mg</title>
          <description>Participants with HIV-1 infection received doravirine 25 mg q.d. for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Doravirine 200 mg</title>
          <description>Participants with HIV-1 infection received doravirine 200 mg q.d. for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants with HIV-1 infection received placebo q.d. by mouth for 7 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="5.8"/>
                    <measurement group_id="B2" value="34.8" spread="8.4"/>
                    <measurement group_id="B3" value="26.8" spread="1.0"/>
                    <measurement group_id="B4" value="32.8" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load</title>
        <description>The change from baseline to Day 7 in plasma HIV RNA viral load was determined for each arm. Results are expressed as change in HIV RNA log10 copies/mL after 7 daily doses of doravirine or placebo. It was hypothesized that at least 1 dose of doravirine would be superior to placebo as documented by the upper bound of the 90% confidence interval &lt;-1. Plasma HIV RNA levels were determined using the Abbott RealTime HIV assay which has a linear range from 40 to 10 million copies/mL.</description>
        <time_frame>Baseline and Day 7</time_frame>
        <population>All participants who received ≥1 dose of study drug are included (results are presented according to actual treatment received).</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 25 mg</title>
            <description>Participants with HIV-1 infection received doravirine 25 mg q.d. for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Doravirine 200 mg</title>
            <description>Participants with HIV-1 infection received doravirine 200 mg q.d. for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants with HIV-1 infection received placebo q.d. by mouth for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load</title>
          <description>The change from baseline to Day 7 in plasma HIV RNA viral load was determined for each arm. Results are expressed as change in HIV RNA log10 copies/mL after 7 daily doses of doravirine or placebo. It was hypothesized that at least 1 dose of doravirine would be superior to placebo as documented by the upper bound of the 90% confidence interval &lt;-1. Plasma HIV RNA levels were determined using the Abbott RealTime HIV assay which has a linear range from 40 to 10 million copies/mL.</description>
          <population>All participants who received ≥1 dose of study drug are included (results are presented according to actual treatment received).</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" lower_limit="-1.71" upper_limit="-1.32"/>
                    <measurement group_id="O2" value="-1.41" lower_limit="-1.61" upper_limit="-1.21"/>
                    <measurement group_id="O3" value="-0.15" lower_limit="-0.35" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Doravirine was declared superior to placebo when the upper bound of the 90% CI was &lt;-1.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares (LS) mean difference</param_type>
            <param_value>-1.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-1.60</ci_lower_limit>
            <ci_upper_limit>-1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Doravirine was declared superior to placebo when the upper bound of the 90% CI was &lt;-1.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-1.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.51</ci_lower_limit>
            <ci_upper_limit>-1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of Doravirine on Day 7</title>
        <description>The AUC0-24hr of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
        <time_frame>Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7</time_frame>
        <population>All participants who received ≥1 dose of doravirine are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 25 mg</title>
            <description>Participants with HIV-1 infection received doravirine 25 mg q.d. for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Doravirine 200 mg</title>
            <description>Participants with HIV-1 infection received doravirine 200 mg q.d. for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of Doravirine on Day 7</title>
          <description>The AUC0-24hr of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
          <population>All participants who received ≥1 dose of doravirine are included.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="9.35" upper_limit="13.4"/>
                    <measurement group_id="O2" value="62.2" lower_limit="52.0" upper_limit="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Doravirine on Day 7</title>
        <description>The Cmax of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
        <time_frame>Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7</time_frame>
        <population>All participants who received ≥1 dose of doravirine are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 25 mg</title>
            <description>Participants with HIV-1 infection received doravirine 25 mg q.d. for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Doravirine 200 mg</title>
            <description>Participants with HIV-1 infection received doravirine 200 mg q.d. for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Doravirine on Day 7</title>
          <description>The Cmax of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
          <population>All participants who received ≥1 dose of doravirine are included.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="826" lower_limit="727" upper_limit="938"/>
                    <measurement group_id="O2" value="4300" lower_limit="3790" upper_limit="4890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration 24 Hours Postdose (C24hr) of Doravirine on Day 7</title>
        <description>The C24hr of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
        <time_frame>24 hours postdose on Day 7 (Day 8)</time_frame>
        <population>All participants who received ≥1 dose of doravirine are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 25 mg</title>
            <description>Participants with HIV-1 infection received doravirine 25 mg q.d. for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Doravirine 200 mg</title>
            <description>Participants with HIV-1 infection received doravirine 200 mg q.d. for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration 24 Hours Postdose (C24hr) of Doravirine on Day 7</title>
          <description>The C24hr of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
          <population>All participants who received ≥1 dose of doravirine are included.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251" lower_limit="188" upper_limit="335"/>
                    <measurement group_id="O2" value="1540" lower_limit="1150" upper_limit="2060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Doravirine on Day 7</title>
        <description>The Tmax of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
        <time_frame>Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7</time_frame>
        <population>All participants who received ≥1 dose of doravirine are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 25 mg</title>
            <description>Participants with HIV-1 infection received doravirine 25 mg q.d. for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Doravirine 200 mg</title>
            <description>Participants with HIV-1 infection received doravirine 200 mg q.d. for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Doravirine on Day 7</title>
          <description>The Tmax of doravirine on Day 7 was determined in the doravirine treatment arms.</description>
          <population>All participants who received ≥1 dose of doravirine are included.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after the last dose of study drug (up to 21 days)</time_frame>
      <desc>All participants who received ≥1 dose of study therapy are included. Adverse event d are summarized by study treatment received for the 7-day treatment period and are pooled for the 14-day poststudy period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Doravirine 25 mg</title>
          <description>Participants with HIV-1 infection received doravirine 25 mg q.d. for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Doravirine 200 mg</title>
          <description>Participants with HIV-1 infection received doravirine 200 mg q.d. for 7 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants with HIV-1 infection received placebo q.d. by mouth for 7 days.</description>
        </group>
        <group group_id="E4">
          <title>Poststudy</title>
          <description>AEs from all participants in the study were pooled for the poststudy period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v. 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v. 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

